# Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma

> **NCT02124226** · PHASE3 · UNKNOWN · sponsor: **Universita degli Studi di Catania** · enrollment: 102 (estimated)

## Conditions studied

- Low Dose Methotrexate in Severe Chronic Asthma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02124226
- **Lead sponsor:** Universita degli Studi di Catania
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12
- **Primary completion:** 2022-04
- **Final completion:** 2022-07
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124226, "Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02124226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*